Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0068 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0068 | DRUG | Oral repeating dose |
Inclusion Criteria: * Histologically documented, incurable, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable. * Evaluable or measurable disease * Life expectancy \>= 12 weeks * Adequate hematologic and organ functi...
GDC-0068 is an investigational small molecule being studied for the treatment of solid cancers. It is being developed by Roche Holding AG (ticker: RHHBY) and has completed a Phase 1 clinical trial in patients with refractory solid tumors.
The specific molecular target of GDC-0068 has not been disclosed in the available information. It is a small molecule in development for oncology indications, but its mechanism of action is not specified.
GDC-0068 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market.
GDC-0068 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still in the early stages of clinical testing.
GDC-0068 has one completed clinical trial, identified as NCT01090960. This Phase 1 study evaluated the safety and tolerability of GDC-0068 in 52 patients with refractory solid tumors. The trial was conducted in Spain and enrolled adults aged 18 years and older.